PMID- 26471473
OWN - NLM
STAT- MEDLINE
DCOM- 20160718
LR  - 20191210
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 117
IP  - 4
DP  - 2016 Apr
TI  - Immunocytochemical detection of ERG expression in exfoliated urinary cells 
      identifies with high specificity patients with prostate cancer.
PG  - 686-96
LID - 10.1111/bju.13184 [doi]
AB  - OBJECTIVES: To evaluate the immunocytochemical detection of ERG protein in 
      exfoliated cells as a means of identifying patients with prostate cancer (PCa) 
      before prostate biopsy. MATERIALS AND METHODS: Urine samples (30 mL) were 
      collected after digital rectal examination (DRE) from 159 patients with an 
      elevated age-specific prostate-specific antigen (PSA) and/or an abnormal DRE who 
      underwent prostate biopsy. In all cases, exfoliated urinary cells from half of 
      the urine sample underwent immunocytochemical assessment for ERG protein 
      expression. Exfoliated cells in the remaining half underwent assessment of 
      TMPRSS2:ERG status using either nested reverse-transcriptase (RT)-PCR (151 cases) 
      or fluorescence in situ hybridization (FISH; eight cases). Corresponding tissue 
      samples were evaluated using FISH to determine chromosomal gene fusion tissue 
      status and immunohistochemistry (IHC) to determine ERG protein expression. 
      Results were correlated with clinicopathological variables. RESULTS: The 
      sensitivity and specificity of urinary ERG immunocytochemistry (ICC) for PCa were 
      22.7 and 100%, respectively. ERG ICC results correlated with advanced tumour 
      grade, stage and higher serum PSA. In comparison, urine TMPRSS2:ERG transcript 
      analysis had 27% sensitivity and 98% specificity for PCa detection. On tissue 
      IHC, ERG staining was highly specific for PCa. In all, 52% of cancers harboured 
      foci of ERG staining; however, only 46% of cancers that were found to have ERG 
      overexpression were positive on urine ICC. The ERG ICC results showed strong 
      concordance with urinary RT-PCR and FISH, and tissue IHC and FISH. CONCLUSION: 
      This is the first study to show that cytological gene fusion detection using ICC 
      is feasible and identifies patients with adverse disease markers. ERG ICC was 
      highly specific, but this technique was less sensitive than RT-PCR.
CI  - (c) 2015 The Authors BJU International (c) 2015 BJU International Published by John 
      Wiley & Sons Ltd.
FAU - Pal, Raj P
AU  - Pal RP
AD  - Department of Cancer Studies and Molecular Medicine, University of Leicester, 
      Leicester, UK.
AD  - Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, 
      UK.
FAU - Kockelbergh, Roger C
AU  - Kockelbergh RC
AD  - Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, 
      UK.
FAU - Pringle, John Howard
AU  - Pringle JH
AD  - Department of Cancer Studies and Molecular Medicine, University of Leicester, 
      Leicester, UK.
FAU - Cresswell, Lara
AU  - Cresswell L
AD  - Department of Cytogenetics, University Hospitals of Leicester NHS Trust, 
      Leicester, UK.
FAU - Hew, Roger
AU  - Hew R
AD  - Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, 
      Leicester, UK.
FAU - Dormer, John P
AU  - Dormer JP
AD  - Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, 
      Leicester, UK.
FAU - Cooper, Colin
AU  - Cooper C
AD  - Department of Cancer Genetics, University of East Anglia, Norwich, UK.
FAU - Mellon, John Kilian
AU  - Mellon JK
AD  - Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, 
      UK.
FAU - Barwell, Julian G
AU  - Barwell JG
AD  - Department of Genetics, University of Leicester, Leicester, UK.
FAU - Hollox, Edward J
AU  - Hollox EJ
AD  - Department of Genetics, University of Leicester, Leicester, UK.
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150729
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (ERG protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - BJU Int. 2016 Apr;117(4):547-8. PMID: 26969032
MH  - Adenocarcinoma/*diagnosis
MH  - Biopsy, Large-Core Needle
MH  - Early Detection of Cancer
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Prostate/*pathology
MH  - Prostate-Specific Antigen/metabolism
MH  - Prostatic Neoplasms/*diagnosis/*pathology/urine
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Serine Endopeptidases/metabolism
MH  - Trans-Activators/*metabolism
MH  - Transcriptional Regulator ERG
OTO - NOTNLM
OT  - ERG
OT  - gene fusions
OT  - prostate cancer
OT  - protein
OT  - urine
EDAT- 2015/10/17 06:00
MHDA- 2016/07/19 06:00
CRDT- 2015/10/17 06:00
PHST- 2015/10/17 06:00 [entrez]
PHST- 2015/10/17 06:00 [pubmed]
PHST- 2016/07/19 06:00 [medline]
AID - 10.1111/bju.13184 [doi]
PST - ppublish
SO  - BJU Int. 2016 Apr;117(4):686-96. doi: 10.1111/bju.13184. Epub 2015 Jul 29.